PE20001110A1 - Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo - Google Patents
Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activoInfo
- Publication number
- PE20001110A1 PE20001110A1 PE1999001027A PE00102799A PE20001110A1 PE 20001110 A1 PE20001110 A1 PE 20001110A1 PE 1999001027 A PE1999001027 A PE 1999001027A PE 00102799 A PE00102799 A PE 00102799A PE 20001110 A1 PE20001110 A1 PE 20001110A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- pharmaceutical composition
- active agent
- release
- pharmaceutically active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)DE 5% A 50% EN PESO DE UN AGENTE ACTIVO COMO UN INHIBIDOR DE LA HMG-COA REDUCTASA TAL COMO FLUVASTATINA, SIMVASTATINA, ATORVASTATINA, PRAVASTATINA, CERIVASTATINA, MEVASTATINA, LOVASTATINA; b)DE 15% A 50% EN PESO DE HIDROXIPROPILMETILCELULOSA; c)DE 3% A 12% EN PESO DE UN POLIMERO HIDROFILICO NO IONICO TAL COMO HIDROXIETILCELULOSA DE PESO MOLECULAR PROMEDIO 90000 A 1300000; HIDROXIPROPILCELULOSA DE PESO MOLECULAR PROMEDIO 370000 A 1500000 Y POLI(OXIDO DE ETILENO) DE PESO MOLECULAR 100000 A 500000; LA PROPORCION EN PESO DE LA CELULOSA HIDROXIPROPILMETILCELULOSA AL POLIMERO HIDROFILICO NO IONICO ES DE 7:1 A 5:1. LA COMPOSICION ES DE LIBERACION SOSTENIDA POR LO QUE PUEDE MINIMIZAR LA LIBERACION PREMATURA DE PRINCIPIO ACTIVO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17249198A | 1998-10-14 | 1998-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001110A1 true PE20001110A1 (es) | 2000-11-01 |
Family
ID=22627919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999001027A PE20001110A1 (es) | 1998-10-14 | 1999-10-12 | Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1121116B1 (es) |
| JP (2) | JP2002527388A (es) |
| KR (1) | KR100517090B1 (es) |
| CN (1) | CN1196481C (es) |
| AR (2) | AR020780A1 (es) |
| AT (1) | ATE382345T1 (es) |
| AU (1) | AU765475B2 (es) |
| BR (1) | BR9911648A (es) |
| CA (1) | CA2346868C (es) |
| CO (1) | CO5140079A1 (es) |
| CY (1) | CY1107874T1 (es) |
| DE (1) | DE69937891T2 (es) |
| DK (1) | DK1121116T3 (es) |
| ES (1) | ES2297936T3 (es) |
| HK (1) | HK1040920B (es) |
| HU (1) | HUP0104268A3 (es) |
| ID (1) | ID29350A (es) |
| IL (2) | IL142375A0 (es) |
| MY (1) | MY121105A (es) |
| NO (1) | NO327285B1 (es) |
| NZ (1) | NZ511010A (es) |
| PE (1) | PE20001110A1 (es) |
| PL (1) | PL198850B1 (es) |
| PT (1) | PT1121116E (es) |
| RU (1) | RU2259826C2 (es) |
| SK (2) | SK286596B6 (es) |
| TR (1) | TR200101088T2 (es) |
| TW (1) | TW577738B (es) |
| WO (1) | WO2000021525A2 (es) |
| ZA (1) | ZA200103001B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| WO2001093859A1 (en) | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Stable pharmaceutical product and formulation |
| CN1466451B (zh) * | 2000-09-29 | 2010-05-12 | 索尔瓦药物有限公司 | 不受离子强度影响的持续释放的医药制剂 |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| US20060039974A1 (en) * | 2002-09-11 | 2006-02-23 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
| CA2520197A1 (en) | 2003-04-23 | 2004-11-04 | Ferring B.V. | Sachet for a pharmaceutical composition |
| US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| EP1940391A4 (en) * | 2005-08-05 | 2010-01-20 | Orbus Pharma Inc | STABILIZED PHARMACEUTICAL COMPOSITIONS WITH EXTENDED RELEASE WITH AN HMG COA REDUCTASE INHIBITOR |
| US20080033030A1 (en) * | 2006-02-24 | 2008-02-07 | Capua Simona D | Fluvastatin sodium pharmaceutical compositions |
| RU2342144C1 (ru) * | 2007-04-05 | 2008-12-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтический состав, обладающий противосудорожным и психотропным действием |
| RU2356532C2 (ru) * | 2007-06-01 | 2009-05-27 | Открытое Акционерное Общество "Отечественные Лекарства" | Фармацевтическая композиция проксодолола с контролируемым высвобождением |
| CN102805739B (zh) * | 2012-04-10 | 2013-08-14 | 宋芸 | 氟伐他汀钠缓释包衣滴丸及其制备方法 |
| AU2014205356A1 (en) * | 2013-01-09 | 2015-07-30 | Edgemont Pharmaceuticals Llc | Controlled release formulations of lorazepam |
| CN106344535B (zh) * | 2016-08-29 | 2019-09-20 | 济南康和医药科技有限公司 | 一种氟伐他汀钠微孔渗透泵控释片及其制备方法 |
| CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
| EP3720434A4 (en) | 2017-12-05 | 2021-09-01 | Sunovion Pharmaceuticals Inc. | NON-RACEMIC MIXTURES AND THEIR USE |
| SG11202102204PA (en) | 2018-09-25 | 2021-04-29 | Ponce De Leon Health Designated Activity Company | Process of making calcium alpha-ketoglutarate |
| PH12021553056A1 (en) | 2019-06-04 | 2023-09-11 | Sunovion Pharmaceuticals Inc | Modified release formulations and uses thereof |
| KR20220044478A (ko) * | 2019-06-10 | 2022-04-08 | 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 | 알파-케토글루타레이트의 지속 방출 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4915954A (en) * | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
| EP0465096A1 (en) * | 1990-06-26 | 1992-01-08 | Merck & Co. Inc. | Plasma cholesterol level lowering composition |
| ZA959221B (en) * | 1994-11-02 | 1997-04-30 | Janssen Pharmaceutica Nv | Cisapride extended release |
| AU706628B2 (en) * | 1995-07-03 | 1999-06-17 | Sankyo Company Limited | Treatment of arteriosclerosis and xanthoma |
| GB9523752D0 (en) * | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
| DE122011000014I1 (de) * | 1995-12-22 | 2011-11-03 | Kowa Co | Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium. |
| SE9603667D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
-
1999
- 1999-10-05 CO CO99062951A patent/CO5140079A1/es unknown
- 1999-10-12 CN CNB998120812A patent/CN1196481C/zh not_active Expired - Lifetime
- 1999-10-12 KR KR10-2001-7004708A patent/KR100517090B1/ko not_active Expired - Lifetime
- 1999-10-12 EP EP99947489A patent/EP1121116B1/en not_active Revoked
- 1999-10-12 SK SK5054-2008A patent/SK286596B6/sk not_active IP Right Cessation
- 1999-10-12 ES ES99947489T patent/ES2297936T3/es not_active Expired - Lifetime
- 1999-10-12 JP JP2000575501A patent/JP2002527388A/ja active Pending
- 1999-10-12 PE PE1999001027A patent/PE20001110A1/es not_active IP Right Cessation
- 1999-10-12 NZ NZ511010A patent/NZ511010A/en not_active IP Right Cessation
- 1999-10-12 AU AU60909/99A patent/AU765475B2/en not_active Expired
- 1999-10-12 ID IDW20010807A patent/ID29350A/id unknown
- 1999-10-12 DK DK99947489T patent/DK1121116T3/da active
- 1999-10-12 HU HU0104268A patent/HUP0104268A3/hu not_active Application Discontinuation
- 1999-10-12 CA CA002346868A patent/CA2346868C/en not_active Expired - Lifetime
- 1999-10-12 AR ARP990105146A patent/AR020780A1/es not_active Application Discontinuation
- 1999-10-12 DE DE69937891T patent/DE69937891T2/de not_active Expired - Lifetime
- 1999-10-12 TR TR2001/01088T patent/TR200101088T2/xx unknown
- 1999-10-12 IL IL14237599A patent/IL142375A0/xx unknown
- 1999-10-12 BR BR9911648-0A patent/BR9911648A/pt not_active Application Discontinuation
- 1999-10-12 PT PT99947489T patent/PT1121116E/pt unknown
- 1999-10-12 PL PL348109A patent/PL198850B1/pl unknown
- 1999-10-12 WO PCT/EP1999/007627 patent/WO2000021525A2/en not_active Ceased
- 1999-10-12 HK HK02102698.9A patent/HK1040920B/zh not_active IP Right Cessation
- 1999-10-12 AT AT99947489T patent/ATE382345T1/de active
- 1999-10-12 SK SK509-2001A patent/SK286595B6/sk not_active IP Right Cessation
- 1999-10-12 RU RU2001111882/15A patent/RU2259826C2/ru active
- 1999-10-13 MY MYPI99004430A patent/MY121105A/en unknown
- 1999-10-14 TW TW088117692A patent/TW577738B/zh not_active IP Right Cessation
-
2001
- 2001-04-02 IL IL142375A patent/IL142375A/en not_active IP Right Cessation
- 2001-04-04 NO NO20011695A patent/NO327285B1/no not_active IP Right Cessation
- 2001-04-11 ZA ZA200103001A patent/ZA200103001B/en unknown
-
2006
- 2006-08-14 JP JP2006221194A patent/JP4938383B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-04 CY CY20081100134T patent/CY1107874T1/el unknown
- 2008-11-11 AR ARP080104921A patent/AR069281A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20001110A1 (es) | Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo | |
| ATE293995T1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
| AR040588A1 (es) | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa | |
| CA2385890A1 (en) | Controlled release compositions comprising nimesulide | |
| BR9913221A (pt) | Composições catalisadoras sustentadas altamente ativas | |
| MA31432B1 (fr) | Metabolites de derives de (thio) carbamoyl-cyclohexane | |
| AR041089A1 (es) | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
| PE20020254A1 (es) | Derivados de piridina | |
| BR0215184A (pt) | composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada | |
| DE60142891D1 (de) | Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung | |
| MX339071B (es) | Almidon pregelatinizado en una formulacion de liberacion controlada. | |
| IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
| PL358103A1 (pl) | Hydrofilowe molekularne roztwory dyspersyjne karwedilolu | |
| TR200200518T2 (tr) | Felç, Diyabet ve/veya Konjesif Kalp Yetmezliğinin Önlenmesinde Kullanılan Farmolojik Formulasyonlar | |
| CA2294812A1 (fr) | Composition pharmaceutique solide contenant des derives de benzofuranne | |
| UA92920C2 (ru) | Таблетка с насечкой, включающая питавастатин, и имеющая превосходную фотостабильность | |
| ATE236619T1 (de) | Arzneimittel zur verzögerten freisetzung des hmg- coa reduktase inhibitors fluvastatin | |
| NO20040153L (no) | Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes | |
| CO5190673A1 (es) | Nueva composicion y uso liberacion modificada | |
| RU2008102238A (ru) | Таблетка, содержащая труднорастворимый активный ингредиент | |
| WO2004069187A3 (en) | Drug formulation and delivery using crystalline methylated cyclodextrins | |
| TR200100059T2 (tr) | Yeni antimikrobik bileşimler | |
| DK1411956T3 (da) | Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV | |
| HK1041444A1 (zh) | 用於治療hiv感染的包含peg-天冬酰胺酶的藥物組合物 | |
| AR022647A1 (es) | Proceso para preparar una formulacion de liberacion sostenida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| MK | Expiration of term |